Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Skin Carcinoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
3 drugs · 8 active trials
2 drugs · 16 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cemiplimab | Approved | Phase 3 | 15 | 4 | 3 | 25 | 1 | US | Sep 28, 2018 | Apr 7, 2016 |
| Imiquimod | Approved | Phase 3 | 1 | 1 | 1 | 3 | 1 | EU | Sep 18, 1998 | 2001-03 |
| Prednisone | Phase 4 | Phase 4 | 4 | 2 | 0 | 5 | 0 | — | — | Nov 8, 2019 |
| Sirolimus | Phase 4 | Phase 4 | 3 | 2 | 0 | 5 | 0 | — | — | 2013-04 |
| Everolimus | Phase 4 | Phase 4 | 1 | 1 | 0 | 4 | 0 | — | — | 2004-12 |
| Pembrolizumab | Phase 3 | Phase 3 | 17 | 7 | 2 | 29 | 0 | — | — | Feb 5, 2015 |
| Nivolumab | Phase 3 | Phase 3 | 16 | 6 | 1 | 18 | 0 | — | — | Aug 17, 2015 |
| Cetuximab | Phase 3 | Phase 3 | 6 | 2 | 2 | 12 | 0 | — | — | 2005-01 |
| Fluorouracil | Phase 3 | Phase 3 | 4 | 1 | 3 | 11 | 0 | — | — | 1998-10 |
| Cisplatin | Phase 3 | Phase 3 | 4 | 1 | 3 | 6 | 0 | — | — | Feb 1, 2022 |
| Atezolizumab | Phase 3 | Phase 3 | 3 | 2 | 1 | 7 | 0 | — | — | Apr 7, 2017 |
| Niacinamide | Phase 3 | Phase 3 | 3 | 3 | 1 | 4 | 0 | — | — | Dec 3, 2018 |
| Docetaxel | Phase 3 | Phase 3 | 3 | 2 | 1 | 3 | 0 | — | — | Apr 21, 2022 |
| Carboplatin | Phase 3 | Phase 3 | 2 | 0 | 2 | 3 | 0 | — | — | Mar 13, 2023 |
| Dabrafenib | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Aug 17, 2015 |
| Trametinib | Phase 3 | Phase 3 | 2 | 1 | 1 | 2 | 0 | — | — | Aug 17, 2015 |
| Bevacizumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | 2001-07 |
| Paclitaxel | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Jun 8, 2023 |
| Methyl Aminolevulinate | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | Oct 18, 1999 |
| Ipilimumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Jan 30, 2017 |
| Capecitabine | Phase 2 | Phase 2 | 2 | 0 | 0 | 5 | 0 | — | — | 2013-03 |
| Cyclophosphamide | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 1998-10 |
| Binimetinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Mitomycin | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jan 2, 2020 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2012-06 |
| Daromun | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Sep 2, 2020 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2007-11 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 11, 2020 |
| Sonidegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 23, 2019 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Sep 27, 2017 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Aldesleukin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 10, 2026 |
| Avelumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 17, 2019 |
| Bleomycin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 23, 2023 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Disitamab Vedotin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 1, 2026 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Lifileucel | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 10, 2026 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Sintilimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 1, 2026 |
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.